3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase 1/2
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
18
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
4
Stomach Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Hepatocellular
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Various Advanced Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma, Cutaneous Malignant
1
Lymphatic Metastasis
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Ipilimumab
×
Clear all
NCT03138512
2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3
Completed
1,641 enrolled
21 charts